Study of the treatment of psoriasis by unani medicine
Phase 2
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2020/03/023697
- Lead Sponsor
- ational Research Institute of Unani Medicine for Skin Disorders
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1-Patients of any sex in the age group between 18 and 65 years
2-Patients with clinically diagnosed Taqashshur al-Jild (Psoriasis) of plaque-type
3-Psoriasis area severity index (PASI) of >=10%
Exclusion Criteria
1-Patients aged < 18 years or > 65 years
2-Pregnant and lactating mothers
3-Significant pulmonary/cardiovascular/hepato-renal dysfunction
4-Known cases of Immunocompromised states (HIV/ AIDS, etc.)
5-Patient not willing to attend treatment schedule regularly
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The response to treatment will be assessed using the following parameters: <br/ ><br> <br/ ><br>1. Reduction in Psoriasis Area Severity Index (PASI) <br/ ><br>2-Improvement in Investigators Global Assessment (IGA) <br/ ><br>3-Patientâ??s Global Assessment (PGA) on VAS <br/ ><br>Timepoint: at base line,4wk,8wk,12wk
- Secondary Outcome Measures
Name Time Method To compare the improvement in quality of life in patients with Psoriasis by PGA ON VAS and IGATimepoint: at base line,4wk,8wk and 12wk